Malignant melanoma: Relationship of the human leukocyte antigen class II gene DQB1*0301 to disease recurrence in American Joint Committee on Cancer Stage I or II

Cancer

Volumn 78, Issue 4, 1996, Pages 758-763

  Lee, Jeffrey E ^a,c   Lu, Meisheng ^a   Mansfield, Paul F ^a   Platsoucas, Chris D ^b   Reveille, John D ^a   Ross, Merrick I ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

genes; human leukocyte antigen DQ antigens; melanoma; MHC Class II

Indexed keywords

HLA ANTIGEN CLASS 2;

ADULT; ALLELE; ARTICLE; CANCER STAGING; FEMALE; HLA SYSTEM; HUMAN; MAJOR CLINICAL STUDY; MALE; MARKER GENE; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; RISK FACTOR;

ALLELES; FEMALE; FOLLOW-UP STUDIES; HLA-DQ ANTIGENS; HUMANS; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 0029742870     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960815)78:4<758::AID-CNCR11>3.0.CO;2-U     Document Type: Article

References (32)

1. Balch CM, Soong S-J, Shaw HM, Milton GW, Shaw HM, McGovern VJ, et al. Changing trends in cutaneous melanoma over a quarter century in Alabama, USA, and New South Wales, Australia. Cancer 1983;52:1748-53.
2. Seng-Jaw S, Shaw HM, Balch CM, McCarthy WH, Urist MM, Lee JY. Predicting survival and recurrence in localized melanoma: a multivariate approach. World J Surg 1992;16:191-5.
3. Morton DL, Davtyan DG, Wanek LA, Foshang LJ, Cochran AJ. Multivariate analysis of the relationship between survival and microstage of primary melanoma by Clark level and Breslow thickness. Cancer 1993;71:3737-43.
4. Månsson-Brahme E, Carstensen J, Erhard K, Lagerlöf B, Ringborg U, Rutqvist LE. Prognostic factors in thin cutaneous malignant melanoma. Cancer 1994;73:2324-32.
5. Park KGM, Blessing K, McLaren KM, Watson ACH. A study of thin (<1.5 mm) malignant melanomas with poor prognosis. Br J Plast Surg 1993;46:607-10.
6. Slingluff CL, Dodge RK, Stanley WE, Siegler HF. The annual risk of melanoma progression. Cancer 1992;70:1917-27.
7. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14:7-17.
8. Barth A, Morton DL. The role of adjuvant therapy in melanoma management. Cancer 1995;75:726-34.
9. Lee JE, Reveille JD, Ross MI, Platsoucas CD. HLA-DQB1*0301 association with increased cutaneous melanoma risk, Int J Cancer 1994;59:510-3.
10. Reveille JD, Durban E, MacLeod-St. Clair MJ, Goldstein R, Moreda R, Altman RD, et al. Association of amino acid sequences in the HLA-DQB1 first domain with the antitopoisomerase I - autoantibody response in scleroderma (progressive systemic sclerosis). J Clin Invest 1992;90:973-80.
11. American Joint Committee on Cancer. Malignant melanoma of the skin (excluding eyelid). In: Manual for Staging of Cancer. 4th ed. Philadelphia: J.B. Lippencott, 1992:143-8.
12. Morton DL, Wen DR, Wong JH, Wong JH, Economou JS, Cagle LA, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-9.
13. Ross MI, Reintgen D, Balch CM. Selective lymphadenectomy. Emerging role for lymphatic mapping and sentinel node biopsy in the management of early stage melanoma. Semin Surg Oncol USA 1993;9:219-23.
14. Reintgen DS, Vollmer R, Tso CY, Seigler HF. Prognosis for recurrent stage I malignant melanoma. Arch Surg 1987; 122:1338-42.
15. Cascinelli N, Bufalino R, Marolda R, Belli F, Nava M, Galluzzo D, et al. Regional non-nodal metastases of cutaneous melanoma. Eur J Surg Oncol 1986;12:175-80.
16. Moseley HS, Giuliano AE, Storm FK, Clark WH, Robinson DS, Morton DL. Multiple primary melanoma. Cancer 1979; 43:939-44.
17. Slingluff CL, Vollmer RT, Seigler HF. Multiple primary melanoma. Incidence and risk factors in 283 patients. Surgery 1993;113:330-9.
18. Cannon-Albright L, Goldgar DE, Meyer LJ, Lewis CM, Anderson DE, Fountain JW, et al. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science 1992; 258:1148-52.
19. Ball NJ, Yohn JJ, Morelli JG, Norris DA, Golitz LE, Hoeffler JP. RAS mutations in human melanoma: a marker of malignant progression. J Invest Dermatol 1994;102:285-90.
20. Carr J, Mackie RM. Point mutations in the N-ras oncogene in malignant melanoma and congenital naevi. Br J Dermatol 1994;131:72-7.
21. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264:436-40.
22. Lee JE, Loflin PT, Laud PR, Lu M, Reveille JD, Lawlor DA. The human leukocyte antigen TAP2 gene defines the centromeric limit of melanoma susceptibility on chromosome 6p. Tissue Antigens 1996;47:117-21.
23. Topalian SL, Rivoltini L, Mancini M, Mancini M, Markus NR, Robbins PF, et al. Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyro-sinase gene. Proc Natl Acad Sci USA 1994;91:9461-5.
24. Takahashi T, Chapman PB, Yang SY, Hara I, Vijayasaradhi S, Houghton AN. Reactivity of autologous CD4+ T lymphocytes against human melanoma: evidence for a shared melanoma antigen presented by HLA-DR15. J Immunology 1995;154:772-9.
25. + melanoma. Int Immunol 1993;5:1501-8.
26. Hirayama K, Matsushita S, Kikuchci I, Iuchi M, Ohta N, Sasazuki T. HLA-DQ is epistatic in controlling the immune response to schistsomal antigen in humans. Nature 1987; 327:426-30.
27. Salgame P, Convit J, Bloom BR. Immunological suppression by human CDS+ T cells is receptor dependent and HLA-DQ restricted. Proc Natl Acad Sci USA 1991;88:2598-602.
28. Riley EM, Morris-Jones S, Taylor-Robinson AW, Holder AA. Lymphoproliferative responses to a merozoite surface antigen of Plasmodium falciparum: preliminary evidence for seasonal activation of CD8+/HLA-DQ-restricted suppressor cells. Clin Exp Immunol 1993;94:64-7.
29. Serra HM, Crimi C, Sette A, Celis E. Fine restriction analysis and inhibition of antigen recognition in HLA-DQ-restricted T cells by major histocompatibility complex blockers and T cell receptor antagonists. Eur J Immunol 1993;23:2967-91.
30. Fossum B, Breivik J, Melig GI, Gedde-Dahl III T, Hansen T, Knutssen I, et al. A Kras 13Gly→Asp mutation is recognized by HLA-DQ7 restricted T cells in a patient with colorectal cancer. Modifying effect of DQ7 on established cancers harboring this mutation? Int J Cancer 1994;58:506-11.
31. Andersen LC, Beaty JS, Nettles JW, Seyfried CE, Nepom GT, Nepom BS. Allelic Polymorphism in Transcriptional Regulatory Regions of HLA-DQB Genes. J Exp Med 1991;173:181-92.
32. Nepom GT, Chung J, West KA. Differential expression of HLA-DQB1 alleles in a heterozygous cell line. Immunogenetics 1995;42:143-8.